2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Melanoma
2
Carcinoma, Merkel Cell
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
domatinostat
×
Clear all
NCT04133948
2025-03-10
DONIMI
The Netherlands Cancer Institute
Phase 1/2
Completed
44 enrolled
NCT03278665
2022-02-04
SENSITIZE
4SC AG
Phase 1/2
Completed
40 enrolled